Clin2
NCT07749924Possibly a fitRecruiting

Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer

Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
670 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old.
  • You have been diagnosed with non-muscle-invasive bladder cancer (meaning the cancer has not spread into the bladder muscle).
  • Your bladder cancer is classified as 'intermediate-risk' by your doctor.
  • You had a complete surgery (TURBT) within the last 6 weeks to remove all visible bladder tumors, with no remaining visible cancer.
  • Your urine test (liquid biopsy) after surgery showed no sign of cancer.
  • You are generally well enough to participate, with a performance status of 0-2 (meaning you can do most daily activities).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06735287Recruiting
Bladder-sparing treatment for large bladder cancer

This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.

Nanjing, Jiangsu
NCT07225127Recruiting
Bladder cancer treatment: therapy vs. surgery

This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.

Tampa, Florida
NCT06227065Not yet recruiting· Phase 2
Personalized chemotherapy for low-grade bladder cancer

This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.

Bern
NCT07762586Recruiting· Phase 2
Neoadjuvant chemotherapy for muscle-invasive bladder cancer

This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.

New Brunswick, New Jersey
NCT07043543Not yet recruiting
Adaptive radiation therapy for bladder cancer

This trial tests a new type of radiation therapy that adjusts to your body's changes during treatment. It aims to reduce side effects and improve accuracy for people with bladder cancer.

Dijon, Côte d'or
NCT06537154Recruiting· Phase 2/Phase 3
Neoadjuvant therapy for bladder cancer with active surveillance

This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.

Vancouver, British Columbia

Hear when a new Bladder Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.